Evidence map›Paper›PMID 22689060›Full record

ArticleOncogene2013

Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin.

M I Vitolo, A E Boggs, R A Whipple, J R Yoon, K Thompson, M A Matrone, E H Cho, E M Balzer, S S Martin

Abstract read
In one paragraph

Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. The Pro-Metastatic Roles of ROS.Antioxidants (Basel, Switzerland) · 2026
    Review
  2. Cofilin(s) and Mitochondria: Function Beyond Actin Dynamics.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. OverexpressingOncotarget · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cytoskeletal organization in microtentacles.Experimental cell research · 2017
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M I VitoloUniversity of Maryland Marlene and Stewart Greenebaum NCI Cancer Center, Baltimore, MD 21201, USA.
A E Boggs
R A Whipple
J R Yoon
K Thompson
M A Matrone
E H Cho
E M Balzer
S S Martin

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Vu H. Duong · 2008 to 2026
$51.0M
Vascular Biology Training ProgramT32HL007698 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Rosemary A Kozar, Dudley K. Strickland · 1991 to 2026
$8.7M
Tubulin microtentacles in detached mammary epithelial cellsR01CA124704 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARTIN, STUART S · 2007 to 2025
$5.7M
Targeting microtubule stabilization to reduce breast tumor metastasisR01CA154624 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARTIN, STUART S · 2012 to 2023
$3.4M
NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA124704NCI NIH HHS R01-CA124704NCI NIH HHS R01 CA154624NHLBI NIH HHS T32 HL007698NHLBI NIH HHS T32-HL07698
6 · The paper itself

Abstract

Loss of PTEN tumor suppressor enhances metastatic risk in breast cancer, although the underlying mechanisms are poorly defined. We report that homozygous deletion of PTEN in mammary epithelial cells induces tubulin-based microtentacles (McTNs) that facilitate cell reattachment and homotypic aggregation. Treatment with contractility-modulating drugs showed that McTNs in PTEN(-/-) cells are suppressible by controlling the actin cytoskeleton. Because outward microtubule extension is counteracted by actin cortical contraction, increased activity of actin-severing proteins could release constraints on McTN formation in PTEN(-/-) cells. One such actin-severing protein, cofilin, is activated in detached PTEN(-/-) cells that could weaken the actin cortex to promote McTNs. Expression of wild-type cofilin, an activated mutant (S3A), and an inactive mutant (S3E) demonstrated that altering cofilin phosphorylation directly affects McTNs formation. Chemical inhibition of PI3K did not reduce McTNs or inactivate cofilin in PTEN(-/-) cells. Additionally, knock-in expression of the two most common PI3K-activating mutations observed in human cancer patients did not increase McTNs or activate cofilin. PTEN loss and PI3K activation also caused differential activation of the cofilin regulators, LIM-kinase1 (LIMK) and Slingshot-1L (SSH). Furthermore, McTNs were suppressed and cofilin was inactivated by restoration of PTEN in the PTEN(-/-) cells, indicating that both the elevation of McTNs and the activation of cofilin are specific results arising from PTEN loss. These data identify a novel mechanism by which PTEN loss could remodel the cortical actin network to facilitate McTNs that promote tumor cell reattachment and aggregation. Using isogenic MCF-10A PTEN(-/-) and PIK3CA mutants, we have further demonstrated that there are clear differences in activation of cofilin, LIMK and SSH between PTEN loss and PI3K activation, providing a new evidence that these mutations yield distinct cytoskeletal phenotypes, which could have an impact on tumor biology.

Indexed as

ActomyosinCell AdhesionCell Line, TumorCell Surface ExtensionsClass I Phosphatidylinositol 3-KinasesCofilin 1Epithelial CellsGene Knockout TechniquesHumansLim KinasesMutation, MissensePhosphatidylinositol 3-KinasesPhosphoprotein PhosphatasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseActomyosinCFL1 protein, humanClass I Phosphatidylinositol 3-KinasesCofilin 1LIMK1 protein, humanLim KinasesPhosphatidylinositol 3-KinasesPhosphoprotein PhosphatasesPIK3CA protein, humanProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanSSH1 protein, human

Identifiers

PMID22689060
PMCPMC3671600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.